Orthocell Ltd
OCC
Company Profile
Business description
Orthocell Ltd is engaged in the development, manufacture and commercialisation of collagen-based medical devices and cell therapies for the repair and regeneration of bone, nerve, tendon and cartilage defects. It has one segment regenerative medicine industry in Australia with products sold in Australia and internationally. Its solutions are Remplier, Striate, and Cell Therapies.
Contact
161 Campus Drive
Level 2, Murdoch University
Murdoch
PerthWA6150
AUST: +61 893602888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
stocks
Reporting season was stronger than share prices suggest
What 164 ASX earnings results revealed.
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Part one of a two-part Q&A with PitchBook senior analyst Harrison Rolfes on Anthropic’s business model and why it needs to grow margins, fast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,197.90 | 37.50 | 0.41% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,403.86 | 92.65 | 0.37% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,455.83 | 130.19 | 0.20% |
| NZX 50 Index | 13,911.48 | 19.09 | -0.14% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 9,016.20 | 42.20 | 0.47% |
| SSE Composite Index | 3,960.28 | 18.90 | 0.48% |